Research programme: lysophosphatidic acid receptor inhibitors - Kirin/Debiopharm

Drug Profile

Research programme: lysophosphatidic acid receptor inhibitors - Kirin/Debiopharm

Alternative Names: Debio-0719; Ki16198; Ki16425

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin Brewery
  • Class Small molecules
  • Mechanism of Action Lysophosphatidic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
  • 21 Apr 2010 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 101st Annual Meeting of the American Association for Cancer Research ((AACR-2010)
  • 30 Jan 2007 DEBIO 0719 licensed to Debiopharm Group worldwide, excluding Asia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top